Parallel cd19/cd20 car-activated t-cells are more effective for refractory b-cell lymphoma in vitro and in vivo

HIGHLIGHTS

• who: Yuzhen Yin and colleagues from the Department of Oncology, The Affiliated Shanghai No, People`s Hospital, Nanjing Medical University, Shanghai, China have published the paper: Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo, in the Journal: Evidence-Based Complementary and Alternative Medicine of 18/08/2022
• what: The authors transduced CD19 and CD20 CARs into human T cells in parallel and compared parallel dual CAR19/20 single CAR and tandem CAR19/20 in vitro and in vivo.
• how: The authors . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.